Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Brentuximab Vedotin”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01777152
What this trial is testing

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Who this might be right for
Anaplastic Large-Cell LymphomaNon-Hodgkin LymphomaT-Cell Lymphoma
Seagen Inc. 452
Testing effectiveness (Phase 2)UnknownNCT02098512
What this trial is testing

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Who this might be right for
Hodgkin Lymphoma
New York Medical College 20
Testing effectiveness (Phase 2)WithdrawnNCT01620229
What this trial is testing

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Who this might be right for
Hematopoietic/Lymphoid Cancer
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT02169505
What this trial is testing

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 2
Not applicableStudy completedNCT06295211
What this trial is testing

Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.

Who this might be right for
Hodgkin Lymphoma
Federico II University 32
Testing effectiveness (Phase 2)Study completedNCT02497131
What this trial is testing

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Who this might be right for
Lymphatic Diseases
Fondazione Italiana Linfomi - ETS 25
Testing effectiveness (Phase 2)Study completedNCT02572167
What this trial is testing

Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Seagen Inc. 93
Testing effectiveness (Phase 2)Active Not RecruitingNCT01352520
What this trial is testing

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Who this might be right for
CD-30 Positive Anaplastic Large T-cell Cutaneous LymphomaLymphoma, Primary Cutaneous Anaplastic Large CellLymphomatoid Papulosis+5 more
M.D. Anderson Cancer Center 79
Testing effectiveness (Phase 2)Study completedNCT01508312
What this trial is testing

Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 66
Testing effectiveness (Phase 2)Study completedNCT02467946
What this trial is testing

Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient

Who this might be right for
Clinical EfficacySafety
Centre Antoine Lacassagne 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT01703949
What this trial is testing

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

Who this might be right for
Recurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Hodgkin Lymphoma+1 more
University of Washington 28
Early research (Phase 1)Study completedNCT02616965
What this trial is testing

Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Who this might be right for
Cutaneous T-cell Lymphoma (CTCL)
Fox Chase Cancer Center 16
Testing effectiveness (Phase 2)WithdrawnNCT02729961
What this trial is testing

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-PositiveCD30-Positive Neoplastic Cells PresentSystemic Anaplastic Large Cell Lymphoma
University of Washington
Testing effectiveness (Phase 2)Looking for participantsNCT04745949
What this trial is testing

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Who this might be right for
Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell LymphomaAnn Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma+1 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02588651
What this trial is testing

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Who this might be right for
T-cell LymphomaAngioimmunoblastic T-cell LymphomaHepato-splenic T-cell Lymphoma+3 more
Deepa Jagadeesh 23
Testing effectiveness (Phase 2)UnknownNCT03474133
What this trial is testing

Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)

Who this might be right for
Hodgkin's Lymphoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 80
Testing effectiveness (Phase 2)UnknownNCT05243693
What this trial is testing

Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

Who this might be right for
Relapsed/Refractory Classical Hodgkin Lymphoma
National Cancer Center, Korea 30
Testing effectiveness (Phase 2)UnknownNCT02275598
What this trial is testing

Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
University of Modena and Reggio Emilia 12
Testing effectiveness (Phase 2)UnknownNCT05316246
What this trial is testing

Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

Who this might be right for
NK/T Cell Lymphoma Nos
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)Ended earlyNCT02499627
What this trial is testing

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting

Who this might be right for
Lymphatic Diseases
Fondazione Italiana Linfomi - ETS 43
Next Page
31